ReNeuron Group plc, which has developed a proprietary stem cell-derived, exosome-based, drug delivery platform, announces that on 17th March 2025 the Company’s administrators Cork Gully (“The Administrators”) filed the relevant court documents to confirm that “the purpose of administration has been sufficiently achieved” and notice of the end of administration was filed with the court and the registrar of companies.
Read more here…..